A Targeting Drug Delivery System for Ovarian Carcinoma: Transferrin Modified Lipid Coated Paclitaxel-loaded Nanoparticles

Abstract

The transferring modified lipid coated PLGA nanoparticles, as a targetable vector, were developed for the targeting delivery of anticancer drugs with paclitaxel (PTX) as a model drug to the ovarian carcinoma, which combines the advantages and avoids disadvantages of polymeric nanoparticles and liposomes in drug delivery. A transmission electron microscopy (TEM) confirmed the lipid coating on the polymeric core. Physicochemical characterizations of TFLPs, such as particle size, zeta potential, morphology, encapsulation efficiency, and in vitro PTX release, were also evaluated. In the cellular uptake study, the TFLPs were more efficiently endocytosed by the A2780 cells with high expression of transferrin receptors than HUVEC cells without the transferrin receptors. Furthermore, the anticancer efficacy of TFLPs on the tumor spheroids was stronger than that of lipid coated PLGA nanoparticles (LPs) and PLGA nanoparticles. In the in vivo study, the TFLPs showed the best inhibition effect of the tumor growth for the ovarian carcinoma-bearing mice. In brief, the TFLPs were proved to be an efficient targeting drug delivery system for ovarian carcinoma.

Key words

transferrin modified lipid coated nanoparticles - PLGA - targeting drug delivery system - ovarian carcinoma - paclitaxel

• References

• 1 Shahzad MK, Shin YH. Biological significance of HORMA domain containing protein 1 (HORMAD1) in epithelial ovarian carcinoma. Cancer Lett 2012; 18: 76-85
• 2 Chao HT, Wang L. Low dose histone deacetylase inhibitor, LBH589, potentiates anticancer effect of paclitaxel in epithelial ovarian cancer via PI3K/Akt pathway. Cancer Lett 2012; 2: 29-38
• 3 Gould N, Sill MW, Mannel RS et al. A phase I study with an expanded cohort to assess the feasibility of intravenous paclitaxel, intra peritoneal carboplatin and intra peritoneal paclitaxel in patients with untreated ovarian, fallopian tube or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2012; 125: 54-58
• 4 Despierre E, Lambrechts D. The molecular genetic basis of ovarian cancer and its roadmap towards a better treatment. GynecolOncol 2010; 117: 358-365
• 5 Curtin JP, Blessing JA. Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: a gynecologic oncology group study. J Clin Oncol 2001; 19: 1275-1278
• 6 McGuire WP, Blessing JA. Paclitaxel has moderate activity in squamous cervix cancer. A gynecologic oncology group study. J Clin Oncol 1996; 14: 792-795
• 7 Rose PG, Blessing JA. D.M Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 1999; 17: 2676-2680
• 8 Chua DT, Sham JS. A phase II study of docetaxel and cisplatin as first line chemotherapy in patients with metastatic nasopharyngeal carcinoma. Oral. Oncol 2005; 41: 589-595
• 9 McCarthy JS, Tannock IF. A phase II trial of docetaxel and cisplatin in patients with recurrent or metastaticnasopharyngeal carcinoma. Oral Oncol 2002; 38: 686-690
• 10 Horwitz SB. Taxol (paclitaxel): mechanisms of action. Ann Oncol 1994; 5: 3-6
• 11 Liebmann J, Cook JA. Solvent for paclitaxel, and toxicity. Lancet 1993; 342: 14-28
• 12 Sznitowska M, Klunder M, Placzek M. Paclitaxel solubility in aqueous dispersions and mixed micellar solutions of lecithin. Chem Pharm Bull 2008; 56: 70-74
• 13 Zhang L, Langer RS. Nanoparticles in Medicine: Therapeutic Applications and Developments. Clin Pharmacol Ther 2008; 83: 761-769
• 14 Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. NatRev Drug Discov 2005; 4: 145-160
• 15 Zhang L, Zhang L. Lipid polymer hybrid nanoparticles: synthesis, characterization and applications. Nano Life 2010; 1: 163-173
• 16 Rossiello R, Carriero MV. Distribution of ferritin, transferrin and lactoferrin in breast carcinoma tissue. J Clin Pathol 1984; 37: 51-55
• 17 Shindelman JE, Ortmeyer AE, Sussman HH. Demonstration of the transferrin receptor in human breast cancer tissue. Potential marker for identifying dividing cells. Int J Cancer 1981; 27: 329-334
• 18 Jin C, Bai L. Cytotoxicity of paclitaxel incorporated in PLGA nanoparticles on hypoxic human tumor cells. Pharm Res 2009; 26: 1776-1784
• 19 Yang XJ, Koh CG. Transferrin Receptor-Targeted Lipid Nanoparticles for Delivery of an Antisense Oligodeoxyribonucleotide against Bcl-2. Mol Pharm 2009; 6: 221-230
• 20 Chiu SJ, Liu SJ. Efficient delivery of a Bcl-2-specific antisense oligodeoxyribonucleotide (G3139) via transferrin receptor-targeted liposomes. J Controlled Release 2006; 112: 199-207
• 21 Du J, Lu WL, Ying X et al. Dual-targeting to potecan liposomes modified with tamoxifen and wheat germ agglutinin significantly improve drug transport across the blood-brain barrier and survival of brain tumor-bearing animals. Mol Pharm 2009; 6: 905-917
• 22 Kobayashi H, Man S, Graham CH et al. Acquired multicellular-mediated resistance to alkylating agents in cancer. Proc Natl Acad Sci USA 1993; 90: 3294-3298